We are thrilled to announce that NatureMetrics has successfully raised $25 million in its latest funding round, underscoring the strong demand for innovative solutions to biodiversity monitoring and reporting. As a world leader in delivering nature data and intelligence, NatureMetrics leverages cutting-edge technologies such as environmental DNA (eDNA), Earth Observation (EO), and advanced data science and AI to provide actionable insights that help businesses measure their impact on biodiversity effectively. The influx of capital will be instrumental in advancing our Nature Intelligence Platform, which is revolutionizing how firms across various sectors report their nature impact. With this additional funding, we aim to enhance our scalable solutions that empower over 500 clients spanning more than 100 countries to meet new nature reporting commitments mandated by global sustainability initiatives. This achievement coincides with our recognition as an Earthshot Prize finalist and being listed among Bloomberg's Top 25 UK Startups to Watch, solidifying our position as innovators in the environmental sector. As we continue to push the boundaries of technology and data science, we remain committed to driving impactful change and fostering collaboration in the fight against biodiversity loss. Thank you to our investors for their confidence in our mission; together, we look forward to building a healthier planet for generations to come.

Fueling the Future: NatureMetrics Secures $25 Million in Series B Funding
Get the full NatureMetrics company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Anveshan
We are a food-tech startup aiming to provide high quality deeply traceable food products. We leverage technologies based on image processing, spectroscopy, blockchain and IOT to provide the best quality food products made traditionally.
$12.7M Series b
today

Caseway
We are the only enterprise AI form platform that replaces internal R&D and manual workflows by building and maintaining fully integrated automation systems, aligned to your data, your processes, and your long-term success. For document-intensive, compliance-driven organizations in regulated industries like insurance, education, finance, healthcare, and government Compelling reason to buy: Who need AI and automation tailored to their unique forms, workflows, and security environment, without having to shoulder R&D risk or manage AI development internally Product category: Our product is an enterprise document form platform Key benefit: That delivers a fully integrated, continuously improving automation system, built and maintained by experts, without upfront AI build costs Key differentiation: Our product is custom-built for each client’s systems and documents, fully integrated and continuously improved through a long-term partnership model, we maintain, debug, adapt, and align incentives to make it work in the real world.
$1.5M Pre-seed
today

Kubera Health
Kubera’s mission is to power a payment ecosystem where contracts are honored, care is rewarded, and waste is eliminated. We deliver contract and payment intelligence that unifies policies, terms, and claims data into one trusted platform — helping healthcare organizations and their partners build fairer contracts, ensure payments flow as intended, and align incentives across the care ecosystem. As healthcare shifts toward new reimbursement models and risk-sharing arrangements, Kubera is building the payment-intelligence backbone that enables multiple parties to adapt faster, protect margins, and dedicate more resources to patient care.
$6.5M Seed
today

Psilera
Psilera is a biotechnology company founded by scientists dedicated to finding better therapeutics for neurological conditions like dementia, addiction, and mental health disorders. Since 2019, Psilera has been focused on early-stage drug discovery & development with a dynamic team of experts in synthetic chemistry, pharmacology, clinical development, and business development.
$8.8M Seed
today

Abstract
Abstract is a venture capital firm based in San Francisco with $1.5 billion in assets under management. We are sector-agnostic, focused on seed and early stage founders. Our reputation among founders is built on fierce loyalty, unparalleled connections, and a relentless drive to help them win.
$59.0M Series a
today
Other recent Series b rounds
Companies that recently closed a Series b round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 | ![]() Anveshan India | Series b | $12.7M | today |
| 2 | ![]() Orbital Industries United Kingdom | Series b | $50.0M | today |
| 3 | ![]() Airis Labs United States | Series b | $60.0M | today |
| 4 | ![]() Phytolon Israel | Series b | $23.6M | 2d ago |
| 5 | ![]() Handle United States | Series b | $27.0M | 3d ago |



